Luxembourg will not be home to either an agency responsible for authorising medical software or a laboratory developing its own artificial intelligence. It will host the centre from which the World Health Organisation intends to help European countries regulate the use of these technologies in healthcare.
1. What is a ‘geographically dispersed’ office?
The term ‘administrative office’ refers to a specialised WHO branch located outside its regional headquarters in Copenhagen. The future office in Luxembourg will therefore be part of WHO/Europe. It will report to its management and serve the 53 Member States in its region, which extends well beyond the European Union.
There are already five such offices. Barcelona is working on the financing of health systems. Venice is focusing on investment in health and development. Almaty specialises in primary healthcare. Istanbul is involved in preparedness for health emergencies. Bonn is home to the European Centre for Environment and Health.
These are generally small organisations. Data published by the WHO for 2024 put the number of employees at existing offices at between six and 23. This range gives an indication of the scale, but the number of people who will be working in Luxembourg has not yet been disclosed.
2. What exactly will this office do?
Its first task will be to translate the general principles on ‘safe, ethical and trustworthy’ AI into practical tools for use by governments, public authorities and healthcare professionals.
The office will be able to identify national practices, compare hospitals’ experiences, draw up recommendations, train professionals and advise governments on developing a strategy. It will also need to assist countries with fewer technical resources.
Let’s take a tool capable of analysing an X-ray or suggesting a diagnosis. Before using it, a hospital must check the quality of the data used to train it, measure its errors, identify any potential biases and decide who remains responsible for the medical decision. It must also protect patient data and train healthcare staff. The WHO office will be working on these kinds of issues.
It will not replace the authorities responsible for authorising medical devices. It will not oversee hospitals in Luxembourg. Nor will its recommendations constitute binding decisions for Member States.
3. Why does the WHO believe that such an office is necessary?
Artificial intelligence has been introduced into healthcare systems more quickly than the regulations designed to govern it.
A study published by the WHO in April 2026 shows that nearly two-thirds of the European Union countries surveyed are already using AI in diagnosis. However, only 8% have a dedicated AI strategy for healthcare. The same proportion has established rules to determine who bears responsibility when a system makes a mistake.
The office will be tasked with helping to narrow this gap. Its work will support the roadmap on artificial intelligence in healthcare for the period 2026-2033, which was submitted to Member States at the same WHO meeting in Copenhagen.
The aim, therefore, is not merely to encourage innovation. It is also to prevent a promising tool from being rolled out without sufficient evidence of its effectiveness, without human oversight or without a clear division of responsibilities.
4. What does Luxembourg actually stand to gain from this?
The first benefit will be institutional. Some of the WHO’s European expertise on AI in healthcare will be generated from Luxembourg. Meetings, training sessions and exchanges with Member States will thus bring public officials, researchers and healthcare professionals from abroad closer to the country.
Hospitals, the University of Luxembourg and public research institutes will find it easier to participate in networks, share their experiences or contribute to international projects. However, this close relationship will not guarantee them contracts, funding or preferential access to WHO decision-making.
The office can also link together several investments already undertaken by the country. In particular, the DigiSanté programme is preparing for the exchange of health data envisaged by the European Health Data Space. The Luxembourg National Data Service is working on ensuring the secure use of this data. Meluxina and the Meluxina-AI project provide computing capacity. The University and research institutes possess expertise in data, personalised medicine and clinical research.
For a foreign company or a researcher, the WHO’s presence will add another element to this ecosystem. It will not automatically transform Luxembourg into the European capital of medical AI. It may, however, strengthen its credibility as a hub where healthcare, data, computing and governance converge.
“Artificial intelligence must help to improve the quality and safety of care, support healthcare professionals and genuinely benefit patients, whilst respecting their rights and their data,” said the minister for health and social security, 
5. What else is needed to gauge the impact of the announcement?
Luxembourg won the competition against Poland and Portugal. It has not yet demonstrated the capabilities to match this victory.
The press release does not specify the opening date, the office’s address or its staff numbers. It does not give a figure for its budget. Nor does it indicate the State’s financial contribution, any premises that may be made available, or the number of posts to be filled in Luxembourg.
These elements should be included in the hosting agreement to be negotiated with the WHO. They will make it possible to distinguish between two very different situations: a small branch office funded largely by the host country, or a regional centre with larger international teams and programmes.
